A Phase 3 Randomized, Open-label (Sponsor-blind), Active-controlled, Parallel-group, Multi-center, Event Driven Study in Dialysis Subjects With Anemia Associated With Chronic Kidney Disease to Evaluate the Safety and Efficacy of Daprodustat Compared to Recombinant Human Erythropoietin, Following a Switch From Erythropoietin-stimulating Agents
A Phase 3 Randomized, Open-label (Sponsor-blind), Active-controlled, Parallel-group, Multi-center, Event Driven Study in Dialysis Subjects With Anemia Associated With Chronic Kidney Disease to Evaluate the Safety and Efficacy of Daprodustat Compared to Recombinant Human Erythropoietin, Following a Switch From Erythropoietin-stimulating Agents
The purpose of this multi-center event-driven study in participants with anemia associated with chronic kidney disease (CKD) to evaluate the safety and efficacy of daprodustat.
Inclusion Criteria:
Exclusion Criteria:
Belo Horizonte, Minas Gerais, 30150-221, Brazil
Frýdek-mistek, 738 18, Czechia
Heraklion-Crete, 71110, Greece
Ciudad de México, State of Mexico 14000, Mexico
Zapopan, Jalisco, 45030, Mexico
Forte Da Casa, 2625-437, Portugal
Mytischi, 141009, Russia
Anyang-Si, Gyeonggi-do, 14068, South Korea
Goyang-si, Gyeonggi-do, 411706, South Korea
Taoyuan Hsien, 333, Taiwan
Fife, KY2 5AH, United Kingdom